250 related articles for article (PubMed ID: 25904742)
1. A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.
Klinghoffer RA; Bahrami SB; Hatton BA; Frazier JP; Moreno-Gonzalez A; Strand AD; Kerwin WS; Casalini JR; Thirstrup DJ; You S; Morris SM; Watts KL; Veiseh M; Grenley MO; Tretyak I; Dey J; Carleton M; Beirne E; Pedro KD; Ditzler SH; Girard EJ; Deckwerth TL; Bertout JA; Meleo KA; Filvaroff EH; Chopra R; Press OW; Olson JM
Sci Transl Med; 2015 Apr; 7(284):284ra58. PubMed ID: 25904742
[TBL] [Abstract][Full Text] [Related]
2. Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation.
Frazier JP; Bertout JA; Kerwin WS; Moreno-Gonzalez A; Casalini JR; Grenley MO; Beirne E; Watts KL; Keener A; Thirstrup DJ; Tretyak I; Ditzler SH; Tripp CD; Choy K; Gillings S; Breit MN; Meleo KA; Rizzo V; Herrera CL; Perry JA; Amaravadi RK; Olson JM; Klinghoffer RA
Cancer Res; 2017 Jun; 77(11):2869-2880. PubMed ID: 28364003
[TBL] [Abstract][Full Text] [Related]
3. A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo.
Dey J; Kerwin WS; Grenley MO; Casalini JR; Tretyak I; Ditzler SH; Thirstrup DJ; Frazier JP; Pierce DW; Carleton M; Klinghoffer RA
PLoS One; 2016; 11(6):e0158617. PubMed ID: 27359113
[TBL] [Abstract][Full Text] [Related]
4. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
5. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
Hoffmann J; Schmidt-Peter P; Hänsch W; Naundorf H; Bunge A; Becker M; Fichtner I
Clin Cancer Res; 1999 Aug; 5(8):2198-204. PubMed ID: 10473106
[TBL] [Abstract][Full Text] [Related]
6. Discovery of
Sime W; Jemaà M; Abassi Y; Lasorsa VA; Bonne Køhler J; Hansson K; Bexell D; Michaelis M; Cinatl J; Strand D; Capasso M; Massoumi R
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911859
[TBL] [Abstract][Full Text] [Related]
7. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway.
Jiang L; Wang P; Sun YJ; Wu YJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):265. PubMed ID: 31215501
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
9. Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers.
Timin AS; Peltek OO; Zyuzin MV; Muslimov AR; Karpov TE; Epifanovskaya OS; Shakirova AI; Zhukov MV; Tarakanchikova YV; Lepik KV; Sergeev VS; Sukhorukov GB; Afanasyev BV
ACS Appl Mater Interfaces; 2019 Apr; 11(14):13091-13104. PubMed ID: 30883080
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
11. The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening.
Berger DP; Henss H; Winterhalter BR; Fiebig HH
Ann Oncol; 1990 Sep; 1(5):333-41. PubMed ID: 2261375
[TBL] [Abstract][Full Text] [Related]
12. Multiplexed Evaluation of Microdosed Antineoplastic Agents
Gundle KR; Deutsch GB; Goodman HJ; Pollack SM; Thompson MJ; Davis JL; Lee MY; Ramirez DC; Kerwin W; Bertout JA; Grenley MO; Sottero KHW; Beirne E; Frazier J; Dey J; Ellison M; Klinghoffer RA; Maki RG
Clin Cancer Res; 2020 Aug; 26(15):3958-3968. PubMed ID: 32299817
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
15. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
Jonas O; Landry HM; Fuller JE; Santini JT; Baselga J; Tepper RI; Cima MJ; Langer R
Sci Transl Med; 2015 Apr; 7(284):284ra57. PubMed ID: 25904741
[TBL] [Abstract][Full Text] [Related]
16. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).
Meyer-Losic F; Quinonero J; Dubois V; Alluis B; Dechambre M; Michel M; Cailler F; Fernandez AM; Trouet A; Kearsey J
J Med Chem; 2006 Nov; 49(23):6908-16. PubMed ID: 17154520
[TBL] [Abstract][Full Text] [Related]
17. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
[TBL] [Abstract][Full Text] [Related]
18. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
Márk Á; Hajdu M; Váradi Z; Sticz TB; Nagy N; Csomor J; Berczi L; Varga V; Csóka M; Kopper L; Sebestyén A
BMC Cancer; 2013 May; 13():250. PubMed ID: 23693095
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
Borders EB; Bivona C; Medina PJ
Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
[TBL] [Abstract][Full Text] [Related]
20. Effect of prednisolone pre-treatment on cat lymphoma cell sensitivity towards chemotherapeutic drugs.
Hlavaty J; Ertl R; Mekuria TA; Rütgen B; Tsujimoto H; Walter I; Wolfesberger B
Res Vet Sci; 2021 Sep; 138():178-187. PubMed ID: 34157499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
